Evidence map›Paper›PMID 39292302›Full record

ArticleDiscover nano2024

Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.

Priya Yadav, Arghya Bandyopadhyay, Keka Sarkar

Abstract read
In one paragraph

Article in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Priya Yadav *Department of Microbiology, University of Kalyani, Kalyani, West Bengal, 741235, India.
Arghya Bandyopadhyay *Department of Microbiology, University of Kalyani, Kalyani, West Bengal, 741235, India. arghya.micro@gmail.com.ORCID http://orcid.org/0000-0002-5930-8160
Keka SarkarDepartment of Microbiology, University of Kalyani, Kalyani, West Bengal, 741235, India. keka@klyuniv.ac.in.ORCID http://orcid.org/0000-0002-0700-2207

Funding

DST-Nanomission scheme SR/NM/NS-1447/2014Indian Council for medical research 45/30/2018-NAN/BMSScience and Engineering Research Board under Department of Science and Technology PDF/2018/001043
6 · The paper itself

Abstract

Radiotherapy is prevalently applied for highly effective cancer therapy while the low specificity of radiation is deleterious to the nearby healthy cells. High-Z-based nanomaterials offer excellent radio-enhancement properties while natural products provide radioprotection. Modulation of the radiotherapeutic index via applying nanomaterials is feasible for effective treatment however, the scenario changes when simultaneous protection of non-cancerous cells is required. Here, we report the modulatory radiotherapeutic effect of curcumin conjugated gold nanoparticles in a single nanoformulation to pave the long-awaited hope of a single combination-based, cell-selective radio enhancer, and protectant for cancer radiotherapy. We have validated the effective radiation dose along with the combination of the radio-nano-modulator by a reverse experimentation statistical model. The concept was supported by different sets of experiments, like quantification of ROS generation, cell cycle monitoring, mitochondrial membrane potential measurement, etc. along with gene expression study, and predictive modeling of molecular pathways of the killing mechanism. In conclusion, the nanoconjugate showed a promise to become a candidate for the pH-dependent cell-specific radio-modulator.

Indexed as

Gold-curcumin nanoparticlesIonizing radiationMetal-phytodrug nanoconjugatesOxidative stressProgrammed cell deathRadioprotectionRadiosensitization

Identifiers

PMID39292302
PMCPMC11410751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.